


Laquinimod-d₅

Cat. No.:	HY-13010S		
CAS No.:	1214267-09-0		
Molecular Formula:	C ₁₉ H ₁₂ D ₅ ClN ₂ O ₃		
Molecular Weight:	361.83		
Target:	Isotope-Labeled Compounds; Apoptosis; NF-κB		
Pathway:	Others; Apoptosis; NF-κB		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (276.37 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.7637 mL	13.8186 mL	27.6373 mL
5 mM	0.5527 mL	2.7637 mL	5.5275 mL
10 mM	0.2764 mL	1.3819 mL	2.7637 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Laquinimod-d₅ (ABR-215062-d₅) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research^[1].

REFERENCES

[1]. Varrin-Doyer M, et al. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. *Exp Neurol*. 2014 Dec;262 Pt A:66-71.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA